Lung Cancer

Joachim G. J. V. Aerts, MD, PhD, discusses findings from the phase 3 DENIM trial in patients with mesothelioma, which was presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

The 18th Annual New York Lung Cancers Symposium, scheduled for November 11, 2023, as a live meeting in New York, New York, boasts an agenda that covers a broad range of modern clinical topics.

Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.

The first-line combination of pembrolizumab, lenvatinib, pemetrexed, and platinum-containing chemotherapy did not meet the dual primary end points of overall survival and progression-free survival compared with pembrolizumab plus pemetrexed and platinum-containing chemotherapy in patients with metastatic, nonsquamous non–small cell lung cancer in whom EGFR-, ALK- or ROS1-directed therapies were not indicated.

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy, followed by surgery and adjuvant nivolumab monotherapy, generated a statistically significant and clinically meaningful improvement in event-free survival vs neoadjuvant chemotherapy plus placebo, followed by surgery and adjuvant placebo, in patients with resectable stage IIA to IIIB non–small cell lung cancer.

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.

Melissa L. Johnson, MD, spotlights the early-phase investigation of ifinatamab deruxtecan in advanced solid tumors, discusses the efficacy and safety of the agent in patients with small cell lung cancer, and emphasizes how results from a subgroup analysis support its continued investigation.

Stephen V. Liu, MD, discusses the 5-year overall survival data with atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer.

Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Jia Luo, MD, discusses a retrospective analysis of initial chemotherapy regimens for the treatment of patients with locally advanced and metastatic NUT carcinoma, which was presented at the 2023 IASLC World Conference on Lung Cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with HER2-mutated, advanced non–small cell lung cancer who require systemic treatment after platinum-based chemotherapy with or without immunotherapy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab as adjuvant treatment for adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, reflect on the current state of second-line treatment options for patients with small cell lung cancer.

Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.